Earnings Call · Q2 FY2022·2022-08-06

Q2 22EPS +8.35%·Rev n/aQ1 22EPS +14.04%·Rev n/aQ4 21EPS -6.74%·Rev n/aQ3 21EPS 0.00%·Rev n/a⚠ consensus missing

Passage BIO, Inc. PASG

Stuart Henderson — Vice President of Corporate Development

Edgar Cale — Interim Chief Executive Officer

Mark Forman — Unspecified, likely senior management or clinical lead

Simona King — Unspecified, likely senior management in finance

+0.9%1d on move date+1.0% vs SPY3d+2.4%5d−5.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PASG calls or request research access.

More PASG calls Browse calls Request research access